Skip to search formSkip to main contentSkip to account menu

Fosamax

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Objective: To find out the significance of bone turnover markers in management of osteoporotic patients and correlation to… 
2014
2014
—Fosamax (Alendronate) is an approved drug widely prescribed for osteoporosis treatment and other bone damaging diseases. Fosamax… 
2009
2009
A district court judge in the United States has ruled that the drug maker Merck will not face the risk of “punitive damages” in… 
2008
2008
VOLUME 26 NUMBER 4 APRIL 2008 NATURE BIOTECHNOLOGY Most osteoporosis therapies act by inhibiting osteoclast-mediated bone… 
2008
2008
VOLUME 26 NUMBER 4 APRIL 2008 NATURE BIOTECHNOLOGY Most osteoporosis therapies act by inhibiting osteoclast-mediated bone… 
2007
2007
The 10-year half-life of the bisphosphonate alendronate suggests that its efficacy might persist after discontinuation. To… 
2005
2005
A 10-year study of daily oral alendronate (Fosamax) and a 7-year study of daily oral risedronate (Actonel) indicate that both… 
1999
1999
Data are submitted on results of investigations designed to study mineral density of the osseous tissue in patients with…